RE:RE:RE:RE:INSIDER... Revenu3 wrote: Don't you believe that the news of December 28, 2018 justifies the variation of the action, the big ones would simply have retained the title
The Dec 28, 2018 PressRelease has contributed a lot's to the Share Price, without the Insurance Company paying for Genenews tests there is absolutely no chance for Genenews making money.
Having said that, a lot's of good move have been made by Genenews in 2018.
After the restart of the Billing Process(very big move), the biggest improvement in the last few months was the formation of a new team formed by Jame Tripp CEO, David Byram CCO and Dietrich Stephan (LifeX)
Note: When a CCO (David Byram) come on board of a company it is usually because big increase in revenue are expexted(why pay a big salary for nothing).
In the Conference Call transcrip
https://Plus.google.com/+WeedWarrior/posts/PH11vherjts Jame Tripp admit to having in the past over promised and under delivered.
For the $30 million 2019 revenue estimate, you can be assured that this estimate was not made only by Jame Tripp, but by the new team, Jame Tripp CEO, David Byram CCO and Dietrich Stephan (LifeX).
Three head are more accurate than one.
One more reason for the increase in share price could also have been the result of investors realising that Genenews has become more and more like a real company in it's structure.